Skip to Content

Clinical Trials Detail

RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Objective
This is a clinical trial of cisplatin that will be administered by IV which is standard of care and radiation therapy that will be administered standard of care.
IRB Protocol Number
13-2078
Principal Investigator(s)
DAVID RABEN

Cancer Trials

  • Head and Neck Cancers
Sponsor(s)
RTOG
Contact
MONICA ROBISCHON at 720-848-0661
or MONICA.ROBISCHON@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 6 to 7 weeks. A follow up period will consist of clinic visits for for 3 to 6 months for the first 4 years and then phone contact afterwards. // Eligibility criteria include but are not limited to 18 years or older with salivary gland tumors.